United Therapeutics Corporation - Common Stock (UTHR)
404.81
+100.05 (32.83%)
NASDAQ · Last Trade: Sep 2nd, 5:18 PM EDT
Detailed Quote
Previous Close | 304.76 |
---|---|
Open | 419.63 |
Bid | 404.02 |
Ask | 404.81 |
Day's Range | 402.28 - 436.95 |
52 Week Range | 266.98 - 417.82 |
Volume | 3,141,666 |
Market Cap | 18.17B |
PE Ratio (TTM) | 15.79 |
EPS (TTM) | 25.6 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 697,481 |
Chart
About United Therapeutics Corporation - Common Stock (UTHR)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation. Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need. Read More
News & Press Releases
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · September 2, 2025
Via Benzinga · September 2, 2025
Via Benzinga · September 2, 2025
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Insidestocktwits.com
Via Stocktwits · September 2, 2025
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Togetherstocktwits.com
Via Stocktwits · August 27, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · September 2, 2025
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
Via Benzinga · September 2, 2025
Via Benzinga · September 2, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · September 2, 2025
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.
Via Investor's Business Daily · September 2, 2025
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · September 2, 2025
Via Benzinga · September 2, 2025
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo.
By United Therapeutics Corporation · Via Business Wire · September 2, 2025
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
By United Therapeutics Corporation · Via Business Wire · August 29, 2025
United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors.
Via Chartmill · August 27, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Via StockStory · August 27, 2025
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Via StockStory · August 26, 2025
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · August 25, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Via StockStory · August 19, 2025
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · August 19, 2025
UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech stocks.
Via Chartmill · August 15, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per share was 12.2% below analysts’ consensus estimates.
Via StockStory · August 12, 2025
The company is working through a patent battle that could seriously hamper sales of its new drug.
Via Investor's Business Daily · August 12, 2025
United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors.
Via Chartmill · August 9, 2025
UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech pick with fair valuation.
Via Chartmill · August 6, 2025